IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers
“This IND submission is a seismic leap forward and offers patients an option where there are none,” said Dr. Awah. “Our technology’s unique ability to therapeutically degrade mRNA transcripts redefines what’s possible in biotech. We’re not just innovating—we’re rewriting the future of cancer and disease,” said Dr David T Asuzu MD, PhD, MPH, Chief Medical Officer (Adult Cancers), UTRx Inc. “The validation data supports the technological abilities of engineering mRNA stability elements on the 3’UTR of oncogenes for therapeutic use,” said Dr. Kevin Struhl PhD, co-inventor of the technology and advisor to UTRx Inc, and Professor of Biological Chemistry and Molecular Pharmacology at Harvard University.
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the